425: Launch One Acquisition Corp. Announces Definitive Business Combination with Minovia Therapeutics, Paving Way for Nasdaq Listing

Launch One Acquisition Corp. has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., an Israeli mitochondrial therapy company, which will result in Minovia becoming a publicly traded company on Nasdaq through a new parent entity, Mito US One Ltd. (Pubco).

Summary

• Launch One Acquisition Corp. (SPAC) has signed a Business Combination Agreement with Minovia Therapeutics Ltd. (Minovia), an Israeli company focused on mitochondrial therapies.
• The transaction involves two mergers: Minovia will merge into Mito Sub Israel Ltd. (Company Merger Sub), and Launch One will merge into a newly formed Cayman Islands exempted company (SPAC Merger Sub), with both surviving entities becoming wholly-owned subsidiaries of Mito US One Ltd. (Pubco).
• Pubco will become a publicly traded company, with its ordinary shares listed on Nasdaq, subject to Nasdaq approval.
• The total consideration for Minovia's security holders at closing will be $180 million plus the aggregate net cash proceeds from financing activities between signing and closing, payable in Pubco ordinary shares valued at the SPAC's redemption price.
• Minovia security holders are eligible for an additional $57.5 million in Pubco ordinary shares (Earnout Shares) if Pubco's volume-weighted average share price reaches $11.50 for five consecutive trading days within five years post-closing, or if Minovia begins a Phase 3 clinical trial with the FDA for its Pearson syndrome program or other clinical development programs.
• The transaction is subject to a minimum cash condition requiring SPAC to have at least $23 million in net cash at closing, including funds from its trust account after redemptions and proceeds from transaction financing.
• Minovia is required to secure at least $5 million in bridge financing within 30 days of the agreement's execution, at a pre-money equity valuation of $120 million.
• Additionally, the parties will seek at least $18 million in further transaction financing (excluding committed capital on demand facilities).
• The Sponsor of Launch One will subject 22.5% of its founder shares (1,293,750 shares) to vesting, forfeiture, and transfer restrictions tied to the earnout milestones.
• The post-closing Pubco board will consist of eight directors: five designated by Minovia, one by the Sponsor, and two by Alex Greystoke and Jon Bakhshi (HSC Principals), provided certain conditions are met.
• The CEO and CFO of Pubco post-closing will be the same individuals as Minovia's prior to closing.

Sentiment

Score: 8

Explanation: The announcement of a definitive business combination is a significant positive step for both companies, providing a clear path for Minovia to become publicly traded and access capital. The earnout structure and financing commitments indicate strong future growth potential, despite inherent risks in clinical development and market conditions.

Positives

• The definitive Business Combination Agreement provides a clear path for Minovia Therapeutics to become a publicly traded company on Nasdaq, offering access to public capital markets.
• The earnout structure incentivizes Minovia's former security holders by providing additional consideration tied to future share price performance or significant clinical development milestones, such as initiating a Phase 3 trial or FDA approval.
• The requirement for Minovia to secure at least $5 million in bridge financing and an additional $18 million in transaction financing demonstrates a commitment to funding future operations and clinical programs.
• The post-closing board composition ensures continuity with Minovia's leadership while integrating representation from the SPAC Sponsor and key investors.
• The agreement includes provisions for D&O indemnification and tail insurance, providing protection for current and former directors and officers.

Negatives

• The earnout shares are contingent and subject to specific performance milestones, meaning Minovia security holders may not receive the full $57.5 million if the conditions are not met within the five-year period.
• The Minimum Cash Condition of $23 million, while a safeguard, introduces a potential hurdle for closing if redemptions are high and financing efforts fall short.
• The Sponsor's founder shares are subject to forfeiture if earnout milestones are not achieved, which could impact the Sponsor's overall return.
• The agreement includes standard disclaimers regarding forward-looking statements, highlighting inherent uncertainties and risks that could cause actual results to differ materially.

Risks

• Failure to obtain the Required SPAC Shareholder Approval or Company Shareholder Approval could prevent the transaction from closing.
• Inability to obtain necessary regulatory approvals, including antitrust clearances, Nasdaq listing approval, Israeli Tax Rulings, and ISA Exemptions, could delay or prevent the consummation of the mergers.
• Failure to satisfy the Minimum Cash Condition of $23 million could prevent the closing, unless waived by the Company and Pubco.
• Minovia's ability to secure the required bridge financing of at least $5 million within 30 days, and the additional $18 million in transaction financing, is crucial for the deal's completion and post-closing operations.
• The success of the earnout depends on achieving specific share price targets or clinical development milestones (e.g., Phase 3 clinical trial initiation or FDA Biologics License Application approval), which are subject to inherent risks in pharmaceutical development.
• The FTO Opinion analysis by SPAC's U.S. IP counsel could conclude that Minovia's products or technology are reasonably likely to materially infringe third-party U.S. Patents, potentially leading to termination if a commercially reasonable mitigation plan is not proposed.
• Changes in applicable laws, regulations, political and economic developments, or adverse economic, business, and competitive factors could negatively impact Minovia's business and the anticipated benefits of the combination.
• The risk that the proposed business combination disrupts current plans and operations of Minovia as a result of the announcement and consummation of the proposed business combination.
• Minovia's ability to scale and grow its business, source and retain talent, and maintain key relationships may be affected by the transaction.
• The failure to realize estimated shareholder redemptions, purchase price, and other adjustments could impact the financial outcome of the transaction.

Future Outlook

Pubco is expected to become a publicly traded company on Nasdaq, with Minovia continuing its focus on researching, developing, and advancing mitochondrial therapies, including its Pearson syndrome clinical development program. The company anticipates further clinical trial advancements and potential FDA approvals, which could trigger additional earnout payments to former Minovia security holders.

Management Comments

• The boards of directors of Launch One, Minovia, Pubco, and Company Merger Sub have determined that the transactions are fair, advisable, and in the best interests of their respective companies and shareholders, and have approved the Business Combination Agreement and the transactions contemplated therein.
• The Company's chief executive officer and chief financial officer are expected to enter into new employment agreements with Pubco, effective as of the Closing, ensuring leadership continuity.

Industry Context

This business combination positions Minovia Therapeutics, a company specializing in mitochondrial therapies, to access public markets via a SPAC merger. This trend of biotechnology and pharmaceutical companies utilizing SPACs for public listing has been prevalent, offering a potentially faster route to capital compared to traditional IPOs. Minovia's focus on mitochondrial diseases places it in a specialized and emerging area of the biotech industry, targeting conditions with significant unmet medical needs. The success of such ventures often hinges on clinical trial progress and regulatory approvals, which are explicitly tied to the earnout structure in this agreement.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The document states that there are no pending or threatened material actions against SPAC or Minovia, nor any material orders outstanding, except as disclosed in the respective disclosure schedules (which are not provided in the excerpt).
• General risk factors mention the possibility of legal proceedings being instituted against Launch One, Minovia, or others following the announcement of the proposed business combination.

Related Party Transactions

• Certain Minovia security holders, representing approximately 35% of voting securities, entered into Voting Agreements to support the business combination.
• Key Minovia security holders (officers, directors, or those owning at least 3% of fully-diluted equity) have entered or will enter into Lock-Up Agreements, restricting the transfer of their Pubco shares for one year post-closing, with certain early release conditions.
• Launch One Sponsor LLC (the Sponsor) entered into a Sponsor Agreement, subjecting 22.5% of its founder shares (1,293,750 shares) to transfer restrictions and potential forfeiture based on the achievement of earnout milestones.
• The Sponsor Agreement also includes provisions for additional escrow and transfer restrictions on Sponsor Earnout Shares if the Minimum Cash Condition is not satisfied but waived by Minovia.
• Alex Greystoke and Jon Bakhshi (HSC Principals) entered into a letter agreement (HSC Letter Agreement) agreeing to pay for the costs and expenses of Minovia's U.S. securities counsel and PCAOB auditor.
• Certain contracts involving Minovia and/or its security holders or other related persons are to be terminated at closing, as specified in Schedule 7.3(f)(vii) (not provided in the excerpt).

Stakeholder Impact

• **Shareholders (Launch One)**: Will exchange their SPAC securities for substantially equivalent Pubco securities, with an option to redeem their Class A ordinary shares for cash. Their investment will transition from a SPAC to a operating biotechnology company.
• **Shareholders (Minovia)**: Will exchange their Minovia securities for Pubco ordinary shares, becoming shareholders in a publicly traded entity. They also have a contingent right to additional earnout shares based on future performance.
• **Employees (Minovia)**: Key management (CEO, CFO) will continue in their roles with new employment agreements under Pubco. The new Pubco Equity Plan provides a mechanism for equity-based compensation for employees.
• **Sponsor (Launch One Sponsor LLC)**: Their founder shares are subject to performance-based vesting and forfeiture, aligning their interests with the long-term success of the combined entity and the achievement of earnout milestones.
• **Creditors**: The merger process includes specific notices to creditors in accordance with Israeli law, ensuring their rights are acknowledged during the transaction.

Next Steps

• Minovia to deliver PCAOB audited annual financial statements for 2023 and 2024, and reviewed interim financial statements for H1 2025 to SPAC.
• Minovia to deliver monthly, quarterly, and annual unaudited financial statements to SPAC during the interim period.
• SPAC, Pubco, and Minovia to prepare and file a registration statement on Form F-4 with the SEC, including a proxy statement for SPAC shareholders.
• SPAC to hold a shareholder meeting to vote on the business combination and related matters, including the Pubco Equity Plan and board appointments.
• Minovia to call a shareholder meeting or obtain written consent to approve the business combination.
• Pubco to amend and restate its organizational documents to reflect the new corporate structure.
• Appointment of the Post-Closing Pubco Board, consisting of eight directors.
• Minovia to cause SPAC Merger Sub to be formed in the Cayman Islands and execute a joinder agreement to the Business Combination Agreement.
• Minovia to ensure key individuals, including its CEO and CFO, enter into new employment agreements with Pubco, effective at closing.
• Minovia to ensure all Locked-Up Company Security Holders sign Lock-Up Agreements.
• SPAC to perform a freedom to operate (FTO) analysis regarding Minovia's products and technology, unless waived.
• Minovia and Pubco to obtain Israeli Tax Rulings and ISA Exemptions.
• Minovia to deliver a notice to the Israel Innovation Authority (IIA) immediately after closing.
• Pubco, SPAC, and Minovia to work towards obtaining Nasdaq listing approval for Pubco ordinary shares and public warrants.

Key Dates

Keywords

SPAC, Business Combination, Minovia Therapeutics, Mitochondrial Therapies, De-SPAC, Nasdaq Listing, Earnout, Clinical Trials, Pearson Syndrome, Biologics License Application, FDA, Bridge Financing, Capital Raise, SEC Filing, Form 8-K, Biotechnology, Pharmaceuticals, Corporate Governance, Risk Management